{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:51:22Z","timestamp":1770511882710,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T00:00:00Z","timestamp":1342569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s11126-012-9233-3","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T11:46:48Z","timestamp":1342525608000},"page":"125-135","source":"Crossref","is-referenced-by-count":16,"title":["Quality of Life and Adverse Effects of Olanzapine Versus Risperidone Therapy in Patients with Schizophrenia"],"prefix":"10.1007","volume":"84","author":[{"given":"Katarina Melo","family":"Chaves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Serrano-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana Barbosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Alberto Lira","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlane Coelho Bernardo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"do Socorro Costa Feitosa Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimundo Fernandes","family":"de Ara\u00fajo J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"de Paula Soares Rachetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio","family":"Filgueira J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurigena Antunes","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,18]]},"reference":[{"issue":"1\u20132","key":"9233_CR1","first-page":"53","volume":"1","author":"S Philip","year":"2001","unstructured":"Philip S: Antipsychotic drugs, dopamine receptors, and schizophrenia. Clinical Neuroscience Research 1(1\u20132):53\u201360, 2001","journal-title":"Clinical Neuroscience Research"},{"issue":"1","key":"9233_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","volume":"20","author":"A Abi-Dargham","year":"2005","unstructured":"Abi-Dargham A, Laruelle M: Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20(1):15\u201327, 2005","journal-title":"European Psychiatry"},{"issue":"11","key":"9233_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.mppsy.2008.08.006","volume":"7","author":"PG Michalopoulou","year":"2008","unstructured":"Michalopoulou PG, Shergill SS, Kapur S: New and old antipsychotics: What \u2018effectiveness\u2019 trials tell us. Psychiatry 7(11):443\u2013446, 2008","journal-title":"Psychiatry"},{"issue":"2","key":"9233_CR4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.comppsych.2010.05.008","volume":"52","author":"YC Kao","year":"2011","unstructured":"Kao YC, Liu YP, Chou MK, Cheng TH: Subjective quality of life in patients with chronic schizophrenia: Relationships between psychosocial and clinical characteristics. Comprehensive Psychiatry 52(2):171\u2013180, 2011","journal-title":"Comprehensive Psychiatry"},{"issue":"19","key":"9233_CR5","first-page":"2265","volume":"126","author":"SI Saarni","year":"2010","unstructured":"Saarni SI, Pirkola S: Quality of life of psychiatric patients. Duodecim; laaketieteellinen aikakauskirja 126(19):2265\u20132273, 2010","journal-title":"Duodecim; laaketieteellinen aikakauskirja."},{"key":"9233_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1752-4458-4-31","volume":"4","author":"A Galuppi","year":"2010","unstructured":"Galuppi A, Turola MC, Nanni MG, Mazzoni P, Grassi L: Schizophrenia and quality of life: How important are symptoms and functioning? International Journal of Mental Health Systems 4:31, 2010","journal-title":"International Journal of Mental Health Systems"},{"issue":"3","key":"9233_CR7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","volume":"10","author":"DW Heinrichs","year":"1984","unstructured":"Heinrichs DW, Hanlon TE, Carpenter WT: The quality of life scale\u2014an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10(3):388\u2013398, 1984","journal-title":"Schizophrenia Bulletin"},{"key":"9233_CR8","doi-asserted-by":"crossref","unstructured":"Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, et al.: Quality of life and cognitive dysfunction in people with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 35(1):53\u201359, 2011","DOI":"10.1016\/j.pnpbp.2010.08.018"},{"issue":"3","key":"9233_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4306\/pi.2011.8.3.201","volume":"8","author":"YY Song","year":"2011","unstructured":"Song YY, Kim KR, Park JY, Lee SY, Kang JI, Lee E, et al.: Associated factors of quality of life in first-episode schizophrenia patients. Psychiatry Investigation 8(3):201\u2013206, 2011","journal-title":"Psychiatry Investigation"},{"issue":"1","key":"9233_CR10","first-page":"31","volume":"51","author":"CS Cardoso","year":"2002","unstructured":"Cardoso CS, Bandeira M, Caiaffa WT, Fonseca JOP: Escala de qualidade de vida para pacientes com esquizofrenia QLS-BR: Adapta\u00e7\u00e3o transcultural para o Brasil. Jornal Brasileiro de Psiquiatria 51(1):31\u201338, 2002","journal-title":"Jornal Brasileiro de Psiquiatria"},{"key":"9233_CR11","unstructured":"Brasil MdSd: Aprova o componente especializado da assist\u00eancia farmac\u00eautica. Diario Oficial Uniao, p. 725, 2009"},{"key":"9233_CR12","unstructured":"Manual Diagn\u00f3stico e Estat\u00edstico de Transtornos Mentais\u2014DSM-IV-TR-TM: ArtMed Porto Alegre, 2003"},{"key":"9233_CR13","unstructured":"Brasil Mdsd: Protocolo cl\u00ednico e diretrizes terap\u00eauticas\u2014esquizofrenia refrat\u00e1ria. In: CONASS (Ed) Bras\u00edlia, 2002"},{"issue":"9251","key":"9233_CR14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0140-6736(05)71342-8","volume":"357","author":"D Human","year":"2001","unstructured":"Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001","journal-title":"Lancet"},{"issue":"2","key":"9233_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-079X.2007.00463.x","volume":"43","author":"A Garcia-Navarro","year":"2007","unstructured":"Garcia-Navarro A, Gonzalez-Puga C, Escames G, Lopez LC, Lopez A, Lopez-Cantarero M, et al.: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. Journal of Pineal Research 43(2):195\u2013205, 2007","journal-title":"Journal of Pineal Research"},{"key":"9233_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1\u2013100, 1987","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"4","key":"9233_CR17","first-page":"331","volume":"162","author":"B Carpiniello","year":"2011","unstructured":"Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F: Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study. Clinica Terapeutica 162(4):331\u2013341, 2011","journal-title":"Clinica Terapeutica"},{"issue":"3","key":"9233_CR18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.psychres.2011.03.020","volume":"189","author":"C Cianchetti","year":"2011","unstructured":"Cianchetti C, Ledda MG: Effectiveness and safety of antipsychotics in early onset psychoses: A long-term comparison. Psychiatric Research 189(3):349\u2013356, 2011","journal-title":"Psychiatric Research"},{"key":"9233_CR19","doi-asserted-by":"crossref","unstructured":"Foussias G, Remington G: Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal Of Psychiatry Revue Canadienne de Psychiatrie 55(3):117\u2013125, 2010","DOI":"10.1177\/070674371005500302"},{"issue":"9","key":"9233_CR20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al.: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry 168(9):947\u2013956, 2011","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"9233_CR21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000144895.75728.2b","volume":"24","author":"M Ritsner","year":"2004","unstructured":"Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y: Quality of life outcomes of risperidone olanzapine and typical antipsychotics among schizophrenia patients treated in routine clinical practice\u2014a naturalistic comparative study. Journal of Clinical Psychopharmacology 24(6):582\u2013591, 2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9233_CR22","doi-asserted-by":"crossref","unstructured":"Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D: The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 67(9):1397\u20131403, 2006","DOI":"10.4088\/JCP.v67n0910"},{"key":"9233_CR23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1590\/S0104-12902008000100009","volume":"17","author":"A Le\u00e3o","year":"2008","unstructured":"Le\u00e3o A, Barros S: As representa\u00e7\u00f5es sociais dos profissionais de sa\u00fade mental acerca do modelo de aten\u00e7\u00e3o e as possibilidades de inclus\u00e3o social. Sa\u00fade e Sociedade 17:95\u2013106, 2008","journal-title":"Sa\u00fade e Sociedade"},{"issue":"4","key":"9233_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hup.584","volume":"19","author":"YT Kim","year":"2004","unstructured":"Kim YT, Kang BJ: A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia. Human Psychopharmacology: Clinical and Experimental 19(4):265\u2013269, 2004","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"4","key":"9233_CR25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/026988110101500408","volume":"15","author":"PM Haddad","year":"2001","unstructured":"Haddad PM, Hellewell JSE, Wieck A: Antipsychotic induced hyperprolactinaemia: A series of illustrative case reports. Journal of Psychopharmacology 15(4):293\u2013295, 2001","journal-title":"Journal of Psychopharmacology"},{"key":"9233_CR26","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al.: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. American Journal of Psychiatry 164(3):415\u2013427, 2007"},{"issue":"2","key":"9233_CR27","first-page":"105","volume":"35","author":"A Ciudad","year":"2007","unstructured":"Ciudad A, Alvarez E, Bousono M, Olivares JM, Gomez JC: Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms. Actas Espa\u00f1olas de Psiquiatr\u00eda 35(2):105\u2013114, 2007","journal-title":"Actas Espa\u00f1olas de Psiquiatr\u00eda"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-012-9233-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-012-9233-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-012-9233-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T22:46:40Z","timestamp":1561934800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-012-9233-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,18]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["9233"],"URL":"https:\/\/doi.org\/10.1007\/s11126-012-9233-3","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,18]]}}}